This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Cough variant asthma

Authoring team

In patients with cough variant asthma (CVA), chronic cough is the main (if not the sole) symptom present associated with airway hyperresponsiveness (1).

  • it is considered to be a variant type of asthma as well as a precursor to the development of classical asthma (2)
    • CVA progresses to typical asthma in 17–37% of patients (3)
  • mostly seen in children
  • the patient may be normal during the day time but cough becomes problematic during the night

In these patients eosinophils in sputum, bronchoalveolar lavage (BAL) fluid, and in bronchial biopsy specimens is characteristic (3).

It is important to differentiate CVA from the so-called eosinophilic bronchitis (EB) (1)

  • in eosinophilic bronchitis, patients have cough and eosinophils in sputum but spirometric tests and airway hyperresponsiveness are normal (1)
  • 50% of patients with CVA have associated EB (4).

Reference:

  1. Global Initiative for Asthma (2023). Global Strategy for Asthma Management and Prevention
  2. Matsumoto H et al. Airway wall thickening in patients with cough variant asthma and nonasthmatic chronic cough. Chest. 2007;131(4):1042-9.
  3. Gibson PG, Fujimura M, Niimi A. Eosinophilic bronchitis: clinical manifestations and implications for treatment. Thorax. 2002;57(2):178-82.
  4. Dicpinigaitis PV.Cough. 4: Cough in asthma and eosinophilic bronchitis. Thorax. 2004 Jan;59(1):71-2.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.